Healthcare Market Desk

Biologics Market Size, Share, Production, Growth, Trends, and Forecast 2019-2026

Press release   •   Sep 14, 2019 11:58 EDT

Scope and Methodology

This report provides forecast and analysis of the global biologics market on the global and regional levels. It provides historical data of 2018 along with forecast from 2019 to 2026 in terms of revenue (US$ Mn). The report also includes macroeconomic indicators along with an outlook for biologics revenue annually. It includes drivers and restraints of the global biologics market and their impact on each region during the forecast period. The report also comprises the study of applications and opportunities for biologics manufacturers. It also includes a detailed analysis by product type and supply chain analysis with a list of suppliers and industry stakeholders at each node in the supply chain.

In order to provide users of this report with a comprehensive view of the market, we have included detailed competitiveness analysis, key blockbuster products, clinical pipeline analysis and company players with unique propositions. The dashboard provides a comprehensive comparison of biologics manufacturers on parameters such as revenue sales, ranking of global players, strategic consolidations, i.e. mergers & acquisitions, licensing activities, as well as R&D activities. The study encompasses market attractiveness analysis, product type, application type, and region.

Get Free Sample Copy @ https://www.visionresearchreports.com/report/sample/24893

Segmentation

The report includes the revenue generated from sales of biologics in all regions and important countries in these regions. By product, the global biologics market has been segmented into monoclonal antibodies, vaccines, recombinant hormones/vaccines, cell therapy, gene therapy and other products. By application type, the market is segmented into oncology, infectious diseases, immunology, auto-immune diseases, and other diseases. Furthermore, the global market is sub-segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Market numbers have been estimated based on the annual global and regional sales of key companies; annual production and the revenue of local players is derived from regional pricing trends. Market size and forecast for each segment have been provided in the context of global and regional markets. The global biologics market has been analyzed based on expected demand. Prices considered for the calculation of revenue are regional average prices obtained through primary quotes from numerous regional biologics manufacturers, suppliers, and distributors. All key end users have been considered, and potential applications have been estimated on the basis of secondary sources and feedback from primary respondents. Regional demand patterns have been taken into consideration while assessing the market for various products manufactured in different regions. Top-down approach has been used to estimate the biologics market by regions. Market numbers for global product type and application segments have been derived using the bottom-up approach, which is cumulative of each region’s demand. The company-level market share has been calculated on the basis of revenues reported by key manufacturers. The market has been forecast based on constant currency rates.

Get Complete Report ToC@ https://www.visionresearchreports.com/global-biologics-market-size-share-production-growth-trends-and-forecast-2019-2026/toc/24893

Several primary and secondary sources were consulted during the course of the study. Secondary sources include Factiva, World Bank, FDA, NCBI, Springer Journals, Google Books, Society Publications, Biotechnology Innovation Organization, Arthritis Foundation, British Society for Rheumatology and Hoover’s, as well as company annual reports and publications.

Competitive Landscape

The report provides detailed competitive and company profiles of key participants operating in the global market. Key players in the global biologics market include AbbVie Inc., Amgen Inc, AstraZeneca, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.

The market has been segmented as below:

By Product

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Hormones/Proteins
  • Cell Therapy
  • Gene Therapy
  • Others

By Applications

  • Oncology
  • Infectious Diseases
  • Immunology
  • Autoimmune Diseases
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • RSA
    • Rest of MEA

Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/24893

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Biologics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.2. Overview
4.3. Market Opportunity Map
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Biologics Market Analysis and Forecasts, 2016–2026
4.5.1. Porter’s Analysis
4.5.2. Supply Chain Analysis
4.5.2.1. Product Manufacturers
4.5.2.2. Product Distributors
4.5.2.3. End Users
4.5.3. Market Revenue Projections (US$ Mn)
4.9. Market Outlook

5. Global Biologics Market Analysis and Forecasts, By Product
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Global Biologics Market Value Share Analysis
5.4. Market Value Forecast By Product , 2016–2026
5.4.1. Monoclonal Antibodies
5.4.2. Vaccines
5.4.3. Recombinant Hormones/Proteins
5.4.4. Cell Therapy
5.4.5. Gene Therapy
5.4.6. Others
5.5. Market Attractiveness By Product

6. Global Biologics Market Analysis and Forecasts, By Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Biologics Market Value Share Analysis
6.4. Market Value Forecast By Application , 2016–2026
6.4.1. Oncology
6.4.2. Infectious Diseases
6.4.3. Immunology
6.4.4. Autoimmune Diseases
6.4.5. Others
6.5. Market Attractiveness By Application

7. Global Biologics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Global Growth Scenario
7.3. Market Value Forecast By Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. MEA
7.4. Market Attractiveness By Country/Region

8. North America Biologics Market Analysis and Forecast
8.1. Introduction/ Key findings
8.2. Market Value Forecast By Product , 2016–2026
8.2.1. Monoclonal Antibodies
8.2.2. Vaccines
8.2.3. Recombinant Hormones/Proteins
8.2.4. Cell Therapy
8.2.5. Gene Therapy
8.2.6. Others
8.3. Market Value Forecast By Application , 2016–2026
8.3.1. Oncology
8.3.2. Infectious Diseases
8.3.3. Immunology
8.3.4. Autoimmune Diseases
8.3.5. Others
8.4. Market Value Forecast By Country , 2016–2026
8.4.1. US
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product
8.5.2. By Application
8.5.3. By Country

9. Europe Biologics Market Analysis and Forecast
9.1. Introduction/Key Findings
9.2. Market Value Forecast By Product , 2016–2026
9.2.1. Monoclonal Antibodies
9.2.2. Vaccines
9.2.3. Recombinant Hormones/Proteins
9.2.4. Cell Therapy
9.2.5. Gene Therapy
9.2.6. Others
9.3. Market Value Forecast By Application , 2016–2026
9.3.1. Oncology
9.3.2. Infectious Diseases
9.3.3. Immunology
9.3.4. Autoimmune Diseases
9.3.5. Others
9.4. Market Value Forecast By Country , 2016–2026
9.4.1. Germany
9.4.2. UK
9.4.3. Spain
9.4.4. France
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country

10. Asia Pacific Biologics Market Analysis and Forecast
10.1. Introduction/Key Findings
10.2. Market Value Forecast By Product , 2016–2026
10.2.1. Monoclonal Antibodies
10.2.2. Vaccines
10.2.3. Recombinant Hormones/Proteins
10.2.4. Cell Therapy
10.2.5. Gene Therapy
10.2.6. Others
10.3. Market Value Forecast By Application , 2016–2026
10.3.1. Oncology
10.3.2. Infectious Diseases
10.3.3. Immunology
10.3.4. Autoimmune Diseases
10.3.5. Others
10.4. Market Value Forecast By Country , 2016–2026
10.4.1. India
10.4.2. China
10.4.3. Japan
10.4.4. Australia
10.4.5. New Zealand
10.4.6. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country

11. Latin America Biologics Market Analysis and Forecast
11.1. Introduction/Key Findings
11.2. Market Value Forecast By Product , 2016–2026
11.2.1. Monoclonal Antibodies
11.2.2. Vaccines
11.2.3. Recombinant Hormones/Proteins
11.2.4. Cell Therapy
11.2.5. Gene Therapy
11.2.6. Others
11.3. Market Value Forecast By Application , 2016–2026
11.3.1. Oncology
11.3.2. Infectious Diseases
11.3.3. Immunology
11.3.4. Autoimmune Diseases
11.3.5. Others
11.4. Market Value Forecast By Country , 2016–2026
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of LATAM
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country

12. MEA Biologics Market Analysis and Forecast
12.1. Introduction/Key Findings
12.2. Market Value Forecast By Product , 2016–2026
12.2.1. Monoclonal Antibodies
12.2.2. Vaccines
12.2.3. Recombinant Hormones/Proteins
12.2.4. Cell Therapy
12.2.5. Gene Therapy
12.2.6. Others
12.3. Market Value Forecast By Application , 2016–2026
12.3.1. Oncology
12.3.2. Infectious Diseases
12.3.3. Immunology
12.3.4. Autoimmune Diseases
12.3.5. Others
12.4. Market Value Forecast By Country , 2016–2026
12.4.1. South Africa
12.4.2. Saudi Arabia
12.4.3. UAE
12.4.4. Rest of MEA
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country

13. Competition Landscape
13.1. Market Player – Competition Dashboard (By Tier and Size of companies)
13.2. Blockbuster Drug Matrix
13.3. Pipeline snapshot of Key Biological Therapies
13.4. Company Profiles
13.4.1. AbbVie Inc.
13.4.1.1. Company Overview
13.4.1.2. Financials
13.4.1.3. SWOT Analysis
13.4.1.4. Strategic Overview
13.4.2. Amgen Inc.
13.4.2.1. Company Overview
13.4.2.2. Financials
13.4.2.3. SWOT Analysis
13.4.2.4. Strategic Overview
13.4.3. AstraZeneca
13.4.3.1. Company Overview
13.4.3.2. Financials
13.4.3.3. SWOT Analysis
13.4.3.4. Strategic Overview
13.4.4. Bayer AG
13.4.4.1. Company Overview
13.4.4.2. Financials
13.4.4.3. SWOT Analysis
13.4.4.4. Strategic Overview
13.4.5. Eli Lilly and Company
13.4.5.1. Company Overview
13.4.5.2. Financials
13.4.5.3. SWOT Analysis
13.4.5.4. Strategic Overview
13.4.6. F. Hoffmann-La Roche Ltd.
13.4.6.1. Company Overview
13.4.6.2. Financials
13.4.6.3. SWOT Analysis
13.4.6.4. Strategic Overview
13.4.7. GlaxoSmithKline Plc.
13.4.7.1. Company Overview
13.4.7.2. Financials
13.4.7.3. SWOT Analysis
13.4.7.4. Strategic Overview
13.4.8. Johnson & Johnson Services, Inc.
13.4.8.1. Company Overview
13.4.8.2. Financials
13.4.8.3. SWOT Analysis
13.4.8.4. Strategic Overview
13.4.9. Merck & Co., Inc.
13.4.9.1. Company Overview
13.4.9.2. Financials
13.4.9.3. SWOT Analysis
13.4.9.4. Strategic Overview
13.4.10. Novartis AG
13.4.10.1. Company Overview
13.4.10.2. Financials
13.4.10.3. SWOT Analysis
13.4.10.4. Strategic Overview
13.4.11. Pfizer Inc.
13.4.11.1. Company Overview
13.4.11.2. Financials
13.4.11.3. SWOT Analysis
13.4.11.4. Strategic Overview
13.4.12. Sanofi
13.4.12.1. Company Overview
13.4.12.2. Financials
13.4.12.3. SWOT Analysis
13.4.12.4. Strategic Overview

Buy This Premium Report From Here@ https://www.visionresearchreports.com/report/cart/24893